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Abstract
Aims: The extracellular pH of cancer cells is lower than the intracellular pH. Weakly basic anticancer drugs will be protonated
extracellularly and display a decreased intracellular concentration. In this study, we show that copolymeric nanoparticles
(NPs) are able to overcome this ‘‘pH-induced physiological drug resistance’’ (PIPDR) by delivering drugs to the cancer cells
via endocytosis rather than passive diffussion.
Materials and Methods: As a model nanoparticle, Tetradrine (Tet, Pka 7.80) was incorporated into mPEG-PCL. The
effectiveness of free Tet and Tet-NPs were compared at different extracellular pHs (pH values 6.8 and 7.4, respectively) by
MTT assay, morphological observation and apoptotic analysis in vitro and on a murine model by tumor volume
measurement, PET-CT scanning and side effect evaluation in vivo.
Results: The cytotoxicity of free Tet decreased prominently (P,0.05) when the extracellular pH decreased from 7.4 to 6.8.
Meanwhile, the cytotoxicity of Tet-NPs was not significantly influenced by reduced pH. In vivo experiment also revealed that
Tet-NPs reversed PIPDR more effectively than other existing methods and with much less side effects.
Conclusion: The reversion of PIPDR is a new discovered mechanism of copolymeric NPs. This study emphasized the
importance of cancer microenvironmental factors in anticancer drug resistance and revealed the superiority of nanoscale
drug carrier from a different aspect.
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Introduction
Copolymeric nanoparticles (NPs) have been proved to be
effective carriers for the delivery of antitumor agents with some of
them had been brought into clinical use [1–3]. The superiority of
most NPs without active targeting strategies was mainly attributed
to the enhanced permeability and retention (EPR) effect [4–6] and
the sustained release of drugs from the NPs [7]. In this report, by a
series of in vitro and in vivo studies, we are trying to figure out
another important mechanism of the copolymeric NPs: the
reversion of pH-induced physiological drug resistance (PIPDR).
In addition to the genetic or epigenetic changes of cancer cells,
the tumor microenvironment is also a critical factor that is
attracting more and more attention in the latest years. That is
because solid tumors are organ-like structures that are heteroge-
neous and structurally complex [8]. The altered physicochemical
factors in the tumor microenvironment play a vital role in the
resistance to anticancer drugs. The pH value of tumor tissue is a
typical case in point. The extracellular pH value of cancer cells is
lower than that in normal tissue whereas the intracellular pH of
tumor is similar to that of normal tissue [9]. This unusual
intracellular-extracellular pH gradient can influence the effect of
weakly basic agents with an acid dissociation constant (Pka) of 7.5–
9.5. These drugs will be protonated at the extracellular pH of
tumors [8]. As the protonated forms of these agents are less
membrane permeable, they will accumulate mostly outside the
cell. The intracellular part of weakly basic drugs, under this
condition, will not be able to reach a concentration high enough to
kill cancer cells. Raghunand et al. defined this phenomenon as
‘‘physiological drug resistance’’, as distinct from the ‘‘biochemical
drug resistance’’ which is caused by the altered signaling pathway
or expression of proteins. [10]. However, pH is not the only
physiochemical factor that influences drug distributions in the
tumor tissue; other factors such as penetration [11] or interstitial
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apply a more specified label to this phenomenon: ‘‘pH-induced
physiological drug resistance (PIPDR).’’
PIPDR plays an important role in chemotherapy failure first
because this phenomenon occurs in most tumors [12], varying
little with their genetic characteristics; second, an indispensable
part of present chemotherapeutics are weakly basic drugs such as
doxorubicin, mitoxantrone, vincristine and vinblastine, as well as
paclitaxel and docetaxel [8,13]. Studies have revealed that the
cytotoxicity of these drugs is hampered at lower extracellular
tumor pH [8,10,13–16].
A few attempts have been made to overcome PIPDR. CM Lee
et al. [17] treated cancer cells with the co-administration of
doxorubicin and chloroquine (a competing base) or omeprazole
(H
+ pump inhibitor). Raghunand et al. [15] enhanced the in vivo
effectiveness of doxorubicin by the increase of tumor pH (adding
sodium bicarbonate in the drinking water of mice). However, these
methods rely on the use of additional agents (sometimes toxic), or
changing the homeostasis of the body, which may cause inevitable
side effects.
In this paper, we propose that polymeric NPs composed of
amphiphilic block copolymers is a better candidate used to
overcome PIPDR as it is more effective with less toxicity than
other approaches. It is widely accepted that NPs enter cells via
endocytic uptake and release the loading drugs intracellularly
[18,19]. As a result, when the weakly basic drugs are incorporated
into the NPs, the drug inside will enter the cancer cell by
endocytosis. The pH value inside the cancer cells was normal
(around 7.4), basic drugs released in the cytoplasm would remain
its active forms (uncharged forms) and kill the cancer cell
effectively (Fig. 1.).
To verify our hypothesis, Tetrandrine (Tet), a bis-benzylisoqui-
noline alkaloid (Pka 7.80 and logP 5.78, a typical weakly base)
isolated from the dried root of Hang-Fang-Chi (Stephania
tetrandra S. Moore) [20] was incorporated into the copolymer
made of methoxy poly (ethylene glycol)–polycaprolactone (mPEG-
PCL) as a model. The antitumor effect of free Tet and Tet-loaded
NPs (Tet-NPs) was compared at different extracellular pH values
(pH 7.4 and pH 6.8, respectively). We also evaluated the
antitumor efficacy of the NPs in tumor xenografts in a murine
model with acidic and alkalinized extracellular pH to estimate the
NPs’ potential to reverse in vivo PIPDR. Both in vitro and in vivo
studies revealed that the incorporation of Tet into mPEG-PCL
nanoparticles effectively reversed PIPDR of tumors thus enhance
the antitumor efficacy of Tet.
Materials and Methods
Materials
Tetrandrine (molecular formula C38H42N2O6, Molecular
Weight 638.76) was obtained as a powder with a purity of
.98% from Jiangxi Yibo Pharmaceutical Development Company
( Jiangxi, China). Methoxy-polyethyleneglycol (mPEG, MW:
4 kDa) were purchased Nanjing Well Chemical Co.Ltd.
(P.R.China) and was dehydrated by azeotropic distillation with
toluene, and then vacuum dried at 50uC for 12 h before use. e-
caprolactone (e-CL, Aldrich, USA) was purified by drying over
CaH2 at room temperature and distillation under reduced
pressure. Coumarin-6 (Aldrich,USA), Stannous octoate (Sigma,
USA), PVA (Polymerization Degree 500 and Alcoholization
Degree 88%, Shanghai Dongcang International Trading Co.
Ltd. Shanghai China), RPMI 1640 (Gibco, USA), calf blood
serum, (Minhai Bioengineering, Lanzhou, China), and di-
methylthiazoly-2,5-diphenyltetrazolium bromide (MTT, Amersco,
USA) were used as received. Acetonitrile and Methanol (Merck,
Germany) were of chromatogram grade. All the other chemicals
were of analytical grade and were used without further
purification.
Synthesis and characterization of mPEG-PCL copolymer
and NPs
The mPEG-PCL block copolymer was synthesized from
Methoxy-polyethyleneglycol (mPEG), (MW: 4 kDa) and e- capro-
lactone (e-CL) by a ring opening copolymerization and was
characterized by
1HNMR, Gel permeation chromatography
according to our previous study [20]. The Tet-loaded NPs (Tet-
Figure 1. The cause of PIPDR and the reversion of PIPDR by NPs. [D] stands for drugs and [H]
+ stands for the proton.
doi:10.1371/journal.pone.0024172.g001
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copolymer by single O/W emulsion and solvent evaporation
method also according to our previous study [20]. The particle
size, morphology, stability, drug loading content and encapsula-
tion efficiency of the NPs were evaluated (details in Methods S1).
To determine a drug release profile of Tet from the NPs at
different pH values, the lyophilized Tet-NPs were suspended in
1 mL 0.01 M phosphate buffered saline (PBS) at pH 7.4 and 6.8
respectively to form the solutions containing Tet 500 mg/ml
(loaded in NPs, thus the solubility was substantially improved).
The solution was then placed into a pre-swelled dialysis bag with a
12-kDa molecular weight cutoff (Sigma) and immersed into 10 ml
0.01 M PBS of pH 7.4 and pH 6.8 at 37uC. The PBS out of the
dialysis bag were taken out and replaced by 10 mL of fresh PBS at
the predetermined time interval. The concentrations of Tet were
determined using HPLC (
18C column, Agilent Technologies, Ltd.,
the mobile phase consisted of methanol: water=9:1, with 0.5%
Triethylamine. Flow rate of 1 mL/min, the column temperature
was 25uC, the injection volume was 20 mL, the detector was fixed
at a wavelength of 280.0 nm.)
In vitro studies
The in vitro cytotoxicity of free Tet, Tet-NPs at different
extracellular pH values (pH 6.8 and pH 7.4) was determined by
standard MTT assays in different cell lines. Human gastric
carcinoma cell line BGC-823 and MKN-28, human colon cancer
cell line LoVo, human hepatocellular carcinoma cell line HepG2
and mouse liver cancer cell line H22 were obtained from Shanghai
Institute of Cell Biology (Shanghai, China). Human Umbilical
Vein Endothelial Cells (HUVEC) were isolated from umbilical
veins and cultured by our lab.
The tumor cells were grown routinely in a humidified
atmosphere with 5% CO2. The culture medium was RPMI
1640 medium (pH 7.4) supplemented with 10% calf blood serum
and changed every other day. The culture medium of HUVEC
was EGM supplemented with 10% fetal bovine serum. The
toxicity of the blank NPs was also determined by MTT assays at
different extracellular pHs (The culture medium was adjusted to
pH 7.4 and pH 6.8 with 1 M HCL or 1 M NaOH.)
The apoptosis assay was performed using an Annexin V-FITC
Apoptosis Detection Kit (BioVision, Mountain View, CA)
according to the manufacture’s instructions. Briefly, cells were
cultured in 60-mm Petri disks under pH 7.4 and pH 6.8
respectively and allowed to grow to 75–80% confluency. They
were then exposed to free Tet and Tet-NPs at the concentration of
32.0 mM and compared with control cells treated with RPMI1640
or blank NPs for 24 hrs. Then cells were collected and incubated
with Annexin-V-FITC for determining surface exposure of
phosphatidyl serine in apoptotic cells. Analyses were performed
with a FACScan Flow cytometer (Becton Dickinson, Sunnyvale,
CA, USA).
Particle cellular uptake studies
For the cell uptake experiment, LoVo and MKN-28 cells were
seeded onto the glass covers placed in a 6-well plate with RPMI
1640 supplemented with 10% calf blood serum at the density of
5610
5 cells/well. After incubation at 37uC in a humidified
atmosphere with 5% CO2 for 24 hrs, cells were exposed to
medium containing loaded NPs (equaled to coumarin-6 12.5 mg/
mL in medium. When loaded in NPs, the solubility of coumarin-6
was substantially improved). After incubation for 4 hrs, the
suspension was removed and cover glasses were washed 3–4 times
with PBS at 4uC and 37uC sequentially. Then the cells were
observed under a fluorescence microscopy (Zeiss imager A1,
excitation 494 nm, emission 518 nm, magnification=2006).
In vivo antitumor efficacy evaluation
The animal experiments were performed following the
guidelines in the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH
publication No. 85-23, revised 1985) and was approved by the
Ethics Review Board for Animal Studies of Drum Tower Hospital,
Medical School of Nanjing University (DTH ERMA 66.01/
210A/2008).
Male ICR mice were injected subcutaneously at both of the
axillary spaces with 4–6610
6 H22 cells in saline. When the tumors
reached 100–300 mm
3 in volume, the mice were randomly
divided into four groups, with each group being composed of 6
mice. Two groups of the mice were given 200 mM NaHCO3-
supplemented water to drink ad libitum since then. The mice were
treated with different Tet formulations at both axillary spaces
intratumorally according to Table 1. and Fig. 2. The day of Tet
administration was marked as Day0. Animal weights and tumor
measurements were recorded every other day. The tumor volume
was calculated by the formula (W
26L)/2, where W is the tumor
measurement at the widest point, and L is the tumor dimension at
the longest point.
For PET-CT imaging, one mouse from each group was taken
randomly and fasting for 8 hrs before the imaging on Day 5. The
mice were kept in the anesthetized condition during the whole
PET-CT scanning procedure. Around 600 uCi of
18F-FDG was
injected via the tail vein as a radiotracer for imaging. The imaging
studies were performed with a combined PET-CT scanner for
clinical use (Jemini JXL, Philips, USA). High resolution PET
images were acquired with the mice 15–30 min after the
administration of
18F-FDG, and the same field of view was
covered as for CT. PET images were corrected for attenuation and
scatter on the basis of the CT data. The image fusion was
performed by an automatic image fusion system, using vendor-
supplied software.
The Regions of Interest (ROI) was defined by three radiologists
independently and maximum FDG uptake values in the tumor
were obtained for the standard uptake value (SUV) calculated
according to the following formula:
SUV~
18F activity in tissue
total acitivity of injected 18F=body weight
Statistical analysis
Statistical analyses of data were done using Student’s t test. The
data are listed as Mean6SD, and values of P,0.05 were accepted
as a statistically significant difference.
Results
Copolymer synthesis and characterization of the
copolymers and NPs
The number-average molecular weight (Mn) of the copolymer
determined by
1H-NMR was 23691(Fig.S1.and Table.S1.). The
Mn and weight-average molecular weight (Mw) of the copolymer
determined by GPC were 25826 and 43763, respectively (Fig.S2.
and Table.S1.). The polydispersity of the copolymer was 1.69
(Table.S1.). (Details in Results S1).
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polydispersity around 0.054 (Table.S2.). The NPs exhibited a
regular spherical shape and the size was around 300 nm when
observed by TEM and AFM (Fig.S3.). The maximum drug
loading content was 14.38% (Table.S3.).(Details in Results S1).
In vitro release of Tet-NPs at different pH values
Fig. 3. shows the cumulative in vitro release profiles of the NPs
at 37uC in PBS (pH 7.4 and pH 6.8, respectively). At the first
4 hrs, the NPs at both pH values exhibited a burst release. There
was a burst release of more than 30% Tet at pH 7.4 and more
than 50% Tet at pH 6.8. Then Tet in the NPs in both groups
showed a sustained release manner with the release of Tet at
pH 7.4 more sustainable. At 24 h, the release proportions at
pH 7.4 and pH 6.8 were 78% and 64% respectively and at 120 h,
more than 90% Tet was released in both groups.
Copolymeric NPs can reverse PIPDR in cancer cell lines in
vitro
Fig. 4.a–c. shows the PIPDR of free Tet on MNK-28 cell line. It
can be noticed from Fig. 4.a. that when the extracellular pH
decreased from 7.4 to 6.8, the cytotoxicity of free Tet was
hampered significantly (which was also evaluated by increase of
IC50 values, P,0.05, details in Table 2.). The morphologic
changes of MKN-28 cells treated with free Tet at different pH
values (Fig. 4.b) also shows that after treated with Tet for 24 hrs,
most of cells at pH 7.4 shrank and turned round. However, at
pH 6.8, an indispensable part of cells remain their normal shapes.
The difference of the morphologic changes was confirmed by the
apoptosis assay. Fig. 4.c showed that at pH 7.4, 96.9% of the
MKN-28 cells were apoptotic whereas only 34.4% cells get
apoptotic at a lower extracellular pH.
When the same experimental process was conducted using Tet-
NPs, the results were quite different. According to Fig. 4.a9, when
MKN-28 cells were treat with Tet-NPs, the cytotoxicity of Tet-
NPs was not significantly influenced by the change of extracellular
pH value (for IC50s at different pH values, P.0.05, See Table 2.).
The morphologic changes of the cells as well as the apoptotic
proportion of cells treated with Tet-NPs under different pH values
were also similar (Fig. 4.b9, Fig. 4.c9).
Similar results were also obtained on other 4 cancer cell lines.
(Table 2.)
Tet-NPs can reverse PIPDR and attenuated toxicity of Tet
in vivo
Fig. 5. and Fig.S4. shows the growth of tumors in the
experiment groups. At dosage of 15 mg/kg, both free Tet and
Tet-NPs could delay the growth of tumor in a comparatively mild
manner (with the highest tumor inhibition rate around 50%). In
the subgroups treated with or without NaHCO3, Tet-NPs
Figure 2. Administration protocol for in vivo study. The mice were injected s.c. at both of the axillary spaces with 4–6610
6 H22 cells. When the
tumors were 50–150 mm
3 in volume, the mice were randomly divided into two groups. One group of the mice were given 200 mM NaHCO3-
supplemented water to drink ad libitum since then. The mice were treated with free Tet and Tet-NPs respectively at both axillary spaces
intratumorally (for details, see Table 1.).
doi:10.1371/journal.pone.0024172.g002
Table 1. Administraion Protocol.
Group Bicarbonate Left axillary spaces Right axillary spaces
Con - Saline (Con) Blank NPs (Blank Nps)
Exp - Free Tet 15 mg/kg (Free Tet) Tet-NPs 15 mg/kg (Tet-Nps)
Con+NaHCO3 200 mM NaHCO3 Saline (Con NaHCO3) Blank NPs (Blank Nps+NaHCO3)
Exp+NaHCO3 200 mM NaHCO3 Free Tet 15 mg/kg (Free Tet+NaHCO3) Tet-NPs15 mg/kg (Tet-Nps+NaHCO3)
There are totally four groups and eight subgroups in this study. Each group can be divided to two subgroups according to the agents injected to tumors in different
axillary space. The name of each subgroup was indicated in the brackets. (Also see Fig. 2.)
doi:10.1371/journal.pone.0024172.t001
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antitumor effect of the same formulation at different pH values
was compared, free Tet exhibited better antitumor effect in the
mice without NaHCO3 over those with NaHCO3. For the mice
treated with Tet-NPs, there wasn’t prominent difference caused by
NaHCO3 supplement.
The antitumor effect was also evaluated by PET-CT to assess
the metabolic changes in the tumors at the fifth day after drug
administration (Fig. 6.). The metabolic activities of the tumor were
measured semi-quantitatively by SUVs. As to Fig. 6., The two Tet
formulations at both pH values reduced the metabolism of the
tumor significantly (P,0.05). At both pH values, the tumors
treated with Tet-NPs reduced the SUVs more drastically than free
Tet (P,0.05). For the same formulation, when pH increased,
free Tet exhibited better antitumor effect (SUV Free Tet.
SUV Free Tet+NaHCO3 P,0.05). However, the SUVs in tumors
treated with Tet NP didn’t change significantly (P.0.05).
Both local and systemic side effects were found in this study.
The tumors treated with free Tet suffered from severe skin
ulceration while Tet-NPs didn’t cause obvious ulcerations (Fig. 7.b.
The severity of the ulceration was scored according to its area, see
Table.S4.). Free Tet also caused systemic toxicity including body
weight loss, anorexia and decrease of physical activity, etc (Fig. 7.a).
The body weight loss in the Exp+NaHCO3 group was also more
obvious than in the Exp group.
The survival time in the Con and Con+NaHCO3 group was
nearly the same. The Exp group exhibited longer survival time.
However, the survival time in Exp+NaHCO3 group was not
prolonged; it was even shorter than that in the Con+NaHCO3
group (Fig. 8.).
The endocytosis of the NPs is the probable mechanism of
the reversion of PIPDR
Cells (LoVo and MKN-28) co-incubated with coumarin-6-
loaded NPs were observed using fluorescence microscopy and
optical lens (2006). Fig. 9. shows that in both cell lines, coumarin-
6 accumulated in the cytoplasm. In most of the cells, fluorescent
dots could be found at the peripheral region of the cytoplasm (see
the yellow arrows).
The biocompatibility of PEG-PCL NPs
The biocompatibility of the copolymer was evaluated in the
above mentioned five tumor cell lines as well in HUVEC.
Fig. 10.A. indicates that at a concentration of 400 mg/mL, the
viabilities of the four cell lines were around 100%. Mild
heterogeneity existed, however, with the viabilities of HepG2
and MKN-28 a little more than 100% and viabilities of BGC-823,
LoVo and H22 sightly less than 100%. At different pH values, the
viabilities of each cell line didn’t showed significant difference
(P.0.05). In HUVEC (Fig. 10.B.), at the same concentration, the
blank nanoparticles exhibited far less toxicity compared with free
Tet or Tet-loaded nanoparticles.
Discussion
The rapid development of anticancer drug delivery systems has
given birth to a variety of novel drug carriers characterized by
copolymeric NPs [21–23]. Considerable research efforts have been
given to the synthesis and evaluation of polymers as the drug
carriers. The NPs without active targeting strategy are now the
only category used clinically and commercially [23,24]. However,
Figure 3. In vitro release profile of Tet from the NPs at different pH values. The data were presented as Mean6SD. Where bars are not
shown, SD is less than the height of the points. The figure at the right shows the release profile at the first 12 h as it is not very clear at the original
figure.
doi:10.1371/journal.pone.0024172.g003
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studies. The in vitro effects of them were similar to or just slightly
better than the free drug they load [25–27]. This discrepancy was
merely attributed to the EPR effect and sustained release profile
[4–7]. In this paper, when we focused on the tumor microenvi-
ronment, we figured out another important mechanism: the
reversion of pH-induced physiological drug resistance (PIPDR).
Solid tumors are 3-dimentional structures composed of cancer
cells and stromal cells as well as extracellular matrix and vascular
network [8]. The physicochemical factors in tumor microenviron-
ment are usually different from those in normal tissue. These
altered physicochemical factors are important because they can
influence the efficacy of the anticancer agents. Moreover, these
factors (such as decreased pH, increased interstitial pressure,
impaired penetration, etc.) exist widely in most of the tumors
irrelevant to their primary site, pathological types or genetic
backgrounds and can influence the effect of a great number of
drugs regardless of their mechanisms. Therefore, tumor microen-
vironment has attracted more and more attentions in recent years
[8,28]. Among the microenvironmental factors, pH is of great
importance as the decreased extracellular pH values are detected
in most tumor tissues [12], as a result, focus on tumor extracellular
pH may enhance the effectiveness of a great number of drugs in
almost all kinds of tumors.
In this paper, we firstly confirmed PIPDR on different cancer
cell lines using Tet. According to Fig. 4. and Table 2., the
effectiveness of Tet was hindered significantly as a result of the
decrease of tumor extracellular pH. Here we used Tet because it is
Figure 4. The PIPDR of MKN-28 cells to Tet (Fig. 4.a–c) and the reversion of PIPDR to Tet by incorporating it into PEG-PCL NPs
(Fig. 4.a9–c9). The cytotoxicity of free Tet at different extracelluar pH values. pH 7.4 is the normal pH value used in cell culture while pH 6.8 is the pH
value in most tumor tissues. Similar results can be found in other 3 different digestive cancer cells (Table.S4.). a. The morphological changes of MKN-
28 cells at different extracelluar pH values. (4006). More cells remained normal morphology at lower extracellular pH. b. The apoptosis assay of MKN-
28 cells treated with Tet at different extracelluar pH values. When the extracellular pH value decreased from 7.4 to 6.8, a prominent decrease in
apoptotic ratio could be observed. a9 The cytotoxicity of Tet-NPs at different extracelluar pH values. pH 7.4 is the normal pH value used in cell culture
while pH 6.8 is the pH value in most tumor tissues. Similar results can be found in other three different digestive cancer cells (Table.S4.). b9 The
morphological changes of MKN-28 cells at different extracelluar pH values. (4006). The morphologic changes of MKN-28 cells were similar at both pH
values. c9 The apoptosis assay of MKN-28 cells treated with Tet-NPs at different extracelluar pH values. The apoptotic ratios of the cells didn’t change
with the decrease of extracellular pH.
doi:10.1371/journal.pone.0024172.g004
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Traditional Chinese Herbs, which indicates that PIPDR also
hampers the effect of Traditional Chinese Medicine. Fig. 4. and
Table 2. Also show that the PIPDR can be overcome by
incorporating Tet into NPs. Besides MTT test, we also confirmed
the effectiveness of NPs by apoptosis test and morphologic
observation. These results also explain why the NPs without
active targeting strategies only exhibit prominent superior effects
at in vivo studies. The efficacy of free weakly basic drugs is similar
to NPs at in vitro models with the extracellular pH of 7.4,
however, at pH 6.8 (which resembles the actual situation in vivo),
NPs exhibited significantly better effect.
It should also be noticed that the reversion of PIPDR works by
increasing the intracellular drug concentration, so it could not
improve the antitumor effect of drugs prominently by tens or
hundreds folds. However, as pH is a physiochemical factor
regardless of the genetic background of tumors or the type of
antitumor agents, this new mechanism of the NPs has a wide
influence on a large variety of anticancer agents as well as a large
variety of solid tumors.
We further tested whether NPs can reverse PIPDR in vivo.
Raghunand et al. have proved the existing of PIPDR in
chemotherapeutics nearly 10 years ago and there have been a
couple of studies on the reversion of PIPDR. However, most of
those treatments failed to be brought into clinical use because of
the present or potential toxicity or side effects [15,17,29]. The only
in vivo study about the reversion of PIPDR was reported by
Raghunand et al. [15] in which the bicarbonate-induced
extracellular alkalinization leads to significant improvements in
the therapeutic effectiveness of doxorubicin against MCF-7
xenografts. In the current study, we evaluated the effectiveness
of Tet-NPs and compared their efficacy to Raghunand’s methods.
We evaluated the antitumor effect of free Tet and Tet-NPs under
physiological pH of tumor and increased extracellular pH (by
adding NaHCO3 into drinking water, according to Raghunand’s
report). The mice bore tumors at both of the axillary spaces, each
Table 2. In vitro cytoxicity of Tet-loaded nanoparticles and
free Tet.
Cell lines Formulation IC50 (mM)
pH 7.4 pH 6.8
BGC-823 Free Tet 7.8462.41 13.2461.70*
Tet-NPs 7.0960.43 8.1560.88
#
MKN-28 Free Tet 7.6662.07 11.7160.87*
Tet-NPs 6.5760.60 3.9061.42*
#












Data represent mean value6SD, n=3.
*P,0.05, pH 6.8 vs pH 7.4 for the same formulation (Free Tet or Tet-NPs
respectively).
#P,0.05,Tet-NPs vs Free Tet for the same pH value (pH 6.8 or pH 7.4).
It can be noticed from the table that when the extracellular pH decreased from
7.4 to 6.8, the cytotoxicity of free Tet in all the tumor cell lines attenuated
(which was evaluated by increase of IC50 values, P,0.05). On contrary, the IC50
of Tet-NPs in none of the cell lines increased significantly.
Furthermore, at pH 6.8, the cytotoxicity of Tet-NPs in all the cell lines was more
prominent than free Tet (P,0.05).
doi:10.1371/journal.pone.0024172.t002
Figure 5. Tumor volumes comparison in the experimental groups. The tumor volumes were measured every other day. Each symbol
represents an individual mouse; small horizontal lines indicate the mean.
doi:10.1371/journal.pone.0024172.g005
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identical within each subgroup. Therefore intratumoral injection
was applied. Intratumoral injection can also reduce the influence
of EPR effect [20,27,30] as the agents was delivered directed to the
tumor site. In this case, other mechanisms apart from EPR effect
would stand out.
At both pH values, Tet-NPs exhibited superior antitumor effect
over free Tet. Moreover, the tumor volume increase in Tet-NP
and Tet-NP+NaHCO3 subgroups were similar, which is compli-
ant with in vitro studies, indicating that the antitumor effect of
Tet-NPs was not influenced by tumor pH.
18FDG–PET-CT has
been shown to be a reliable predictor of treatment response in
Figure 6. PET-CT scanning of the mice at the fifth day after treatment. a. For each mouse, the tumor at the left side was injected with saline
or free Tet while the tumor at the right was administrated with Blank or Tet-NPs. b. The SUV values of each group. * indicates that P,0.05 between
the Exp/Blank groups and Con groups. (Exp/Blank vs Con, Exp+NaHCO3/Blank NaHCO3 vs Con NaHCO3). # indicates that P,0.05 between each two
groups linked by lines.
doi:10.1371/journal.pone.0024172.g006
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of early treatment response at the fifth day after administration of
different agents. According to Fig. 6.a and Fig. 6.b, reduced tumor
metabolism was found in all the 4 groups with Tet or Tet-NPs.
When compared the subgroup free Tet to the subgroup free
Tet+NaHCO3, the latter exhibited lower metabolism (P,0.05,
Fig. 6.b), indicating that at day5, the antitumor effect in the
subgroup free Tet+NaHCO3 was better and that of free Tet.
Compared to the free Tet subgroups, Tet-NP subgroups exhibited
lower metabolic activities at both extracellular tumor pH (P.0.05
between Tet-NP and Tet-NP+ NaHCO3 subgroups), which also
confirmed the superiority of NPs regardless of pH values.
Figure 7. The side effects of Free Tet and Tet-NPs. a. The body weight change of the mice during therapy under different treatments. Body
weight loss in this study is not an ideal parameter for the evaluation of wide effects in this study because every mouse received two different
treatments. Nevertheless, the body weight of the Exp+NaHCO3 group was much lower than in the Con+NaHCO3 group while the differences of body
weight between the Exp and Con group was not so obvious. b. Photos of the ulceration taken at the 7th day after administration. (A. Tet-NPs pH 6.8,
B. Free Tet pH 6.8, C. Tet-NPs pH 7.4 and D. Free-Tet pH 7.4). Ulcerations were evaluated in details in Fig.S5.
doi:10.1371/journal.pone.0024172.g007
Figure 8. The survival curve of the mice in different groups. It can be observed that EXP+NaHCO3 failed to improve the survival time of the
mice. Mice in the Exp group without NaHCO3 showed much longer survival time than those in the Exp+NaHCO3 group even though the tumor
burden increases in these two groups were comparable.
doi:10.1371/journal.pone.0024172.g008
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including skin ulceration, body weight loss, anorexia and decrease
of physical activity, etc (Fig. 7. and Fig.S5.), all of which were more
prominent in the subgroups of free Tet. Actually, free Tet caused
so severe skin ulceration that we have to choose a low dosage (with
mild antitumor effect ) in this study. The alleviation of side effects
of Tet-NPs also contributed to their high efficacy. Tet-NPs caused
less side effects compared to free-Tet because Tet-NPs exhibits a
sustainable release pattern, moreover, Tet-NPs enhanced the
intracellular concentration of Tet and thus less Tet would
accumulate in normal tissue. Therefore, compared to systemic
side effects, the alleviation of local effect of Tet-NPs is much more
prominent.
In free Tet subgroups (free Tet and Free Tet+NaHCO3), the
retention of tumor growth was a little more prominent in the
subgroups of free Tet+NaHCO3 on the tumor growth curve,
which seemed different from Raghunand’s report and our in vitro
findings. This discrepancy attributes to three reasons: firstly, in this
study, free Tet caused prominent side effects, which in turn
impaired the effectiveness of Tet and secondly, the accuracy of the
measurement of tumor diameters was hindered by the ulceration
slightly but inevitably. PET-CT scanning indicated that the
glucose metabolism of the tumors in free Tet+NaHCO3 subgroup
was lower than that in the Tet free group, indicating that the
efficacy of free Tet was superior in the subgroup with NaHCO3 at
least during the first days. Thirdly, for free Tet, the side effect was
positively correlated with its antitumor efficacy. The ulceration in
the free Tet+NaHCO3 subgroup was more severe than the
subgroup without NaHCO3 (Fig. 7.b. and Fig.S5.). All these
indicate that for free Tet, the administration of NaHCO3 may
exert effect on the improvement of the effectiveness of Tet, but this
superiority may be hampered considerably by the side effects
caused by free Tet.
As to Raghunand’s report, the use of non-specific alkaloid may
cause metabolic alkalinization and the increased extracellular pH
may also sensitize the toxicity of the antitumor agents to normal
cells such as intestinal epithelium [15]. Contrarily, the effect of
NPs on the reversion of PIPDR is independent of local pH, and
thus causes fewer side effects. Without the addition of another
alkaloid, the NPs treatment will surely gain better patient
compliance in future clinical use. In addition, these results
together with the in vitro biocompatibility study (Fig. 10.) showed
the safety of PEG-PCL nanopartciles.
The survival time is a comprehensive parameter evaluating the
therapeutic effect. It can be observed from Fig. 8. that only the
mice in the Exp group showed longer survival time even though
the tumor volume increases in Exp and Exp+NaHCO3 groups
were comparable. This finding also implicate that the mice may
not actually benefit from NaHCO3 treatment.
For the ability of NPs to reverse PIPDR, there are two possible
mechanisms: (1). Low extracellular pH accelerates the release of
Tet from the NPs and (2). The NPs enter the cells via endocytosis
rather than passive diffusion, which will avoid protonation of
weakly basic drugs outside the cancer cell. Our study shows that
the latter is probably the major mechanism.
Fig. 3. shows the in vitro release of Tet-loaded NPs at different
pH values. At both pH values, the release profile of the NPs was
similar: An initial burst of more than 50% (pH 6.8) and 30%
(pH 7.4) release in the first 4 hrs. Then the release rate of Tet
slowed down and presented a sustained manner. During the tested
time span, the release of Tet from the NPs at pH 6.8 was rapid
than that of pH 7.4. However, the gap between the release
proportions was narrowed gradually with time. At 120 h, more
than 90% of the Tet was released at both pH values (90% for
pH 7.4 and 92% for pH 6.8). Generally, the release profile was
more sustainable at pH 7.4. This difference in release rate
indicates that Tet in the NPs will released in a targeted pattern
at the tumor site where the regional pH is lower. However, as the
difference was not prominent, with the maxium difference about
18%, this may not be the main mechanism of the NP’s reversion of
PIPDR. This can also be concluded from the in vitro toxicity
study: for two cell lines (BGC-823 and HepG2), the antitumor
effect of the NPs didn’t increase at pH 6.8. On the other hand, the
NPs reversed the decrease of antitumor effect of free Tet at lower
pH with significant differences (see Table 2.).
We also looked into the other possible mechanisms by particle
cellular uptake studies. From Fig. 9.a and Fig. 9.b., we found that
after incubation with cancer cells for 4 hrs, fluorescent signals of
Coumarin-6 could be observed inside the cells. As Coumarin-6
was insoluble in water, the intracellular Coumarin-6 was that
originally incorporated in the NPs, which indicated that drugs
could enter the cancer cell using NPs as the carrier. This is in
accordance with the findings that NPs could enter the cancer cell
via endocytosis [16,18,19]. In this case, the Tet loaded in the NPs
would be delivered across the cell membrane in its unionized form.
As the pH value inside the cell was normal (around 7.4), free Tet in
Figure 9. MKN-28 (Fig. 9.a.) and LoVo (Fig. 9.b.) cells incubated
with coumarin-6-loaded NPs. It was obvious that the fluorescent
signal deposited mostly in the peripheral region of cells, with little
fluorescent signal observed inside the nuclei.
doi:10.1371/journal.pone.0024172.g009
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cell efficiently.
There are three two points we want to indicate about this study.
Firstly, an important branch of targeted drug delivery strategy is
pH targeting. For most pH-sensitive drug carriers delivering
anticancer agents, low pH causes acceleration of drug release
usually extracellularly [31–32]. If the loaded drugs are weakly
basic, the released drugs may protonated and accumulate outside
the cells. So we hypothesize here that pH-targeting may not be so
efficacy as it has been supposed. Nevertheless, it still works because
deformation of drug carriers triggered by pH leads to accumula-
tion of NPs and drugs in the tumor tissue, which certainly increase
the specificity of drug delivery and could be more effective than
free drugs. Secondly, as PIPDR is in close relation to the Pka of the
drugs, the choice of appropriate drugs for certain carriers should
be paid close attention to. For example, pH sensitive drug carriers
are more suitable for the delivery of drugs with Pka less than 7
because the effectiveness of weakly acidic drugs is enhanced at
extracellular pH of tumors while carriers of no pH targeting traits
are advised to be chosen for delivery of weakly basic drugs. Also,
the efficacy of new drug delivery system is recommended to be
evaluated at different extracellular pH values in the in vitro study.
Conclusion
In this study, we raised the definition of pH-induced
physiological drug resistance (PIPDR) and confirmed this
phenomenon by experiment. We further proved that copolymeric
nanoparticles (NPs) could reverse PIPDR in vitro and in vivo by a
series of studies. To our best knowledge, this is among the first
reports concentrating on the relationship of NPs and the
physiochemical factors at tumor tissue, which raised some new
considerations on the choice of drugs for different drug carriers as
well as pH-responsive drug delivery systems. We believe that the
findings in this report may exert wide influence because this new
Figure 10. The in vitro toxicity of the blank NPs. Fig. 10.A. shows the toxicity of blank NPs on four tumor cell lines at a concentration of 400 mg/
mL, and the data were presented as Mean6SD. Fig. 10.B. compared the inhibition rate of HUVEC treated with free Tet, Tet-NPs and blank NPs at
different concentrations. The data were presented as Mean6SD. Where bars are not shown, SD is less than the height of the points.
doi:10.1371/journal.pone.0024172.g010
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copolymeric drug carriers, though more studies are still needed to
further confirm this mechanism on other drugs and/or other
polymeric drug carriers.
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